White Paper - Why Diagnostic Regulation Matters in Pharmaceutical Development - and Current Best Practices

Born out of a World CDx Summit, Hanson Wade has partnered with key opinion leaders from Johnson & Johnson, Bristol Myers Squibb, Eli Lilly, Merck, Sanofi, Daiichi Sankyo, Regeneron, and others to provide a critical pharma perspective on the evolving regulatory landscape for biomarkers and companion diagnostics.

Download the white paper to gain:

  • Key insights into the role of diagnostics in pharmaceutical development and regulatory expectations
  • A high-level overview of regulatory environments in the US, EU, Japan, and China
  • Best practices for aligning diagnostic and therapeutic development to drive innovation and improve patient access to precision therapies

What’s more, a handful of the leading authors will be joining a panel at the 15th World Clinical Biomarkers & CDx Summit to take an in-depth discussion on some key challenges discussed in this white paper – see the full panel synopsis here.

Screenshot 2025-07-22 122739
2
Explore the Agenda

Hear the latest translational, clinical and post-approval breakthroughs and gain exclusive insights into precision medicine innovations during our packed agenda, interactive roundtables, and new drug-diagnostic partnerships panel discussions

3
Partner With Us

Position yourself alongside other leading IVD and CDx solution providers to ensure your brand is at the heart of precision medicines deals and collaborations

1
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning a range of precision therapy modalities and indications, and make critical connections during our dedicated networking sessions